|
|
|
|
 |
March
1993
Founded
Ocean Bright Co., Ltd, with working capital of NT$5 million.
May
1993
Signed
an agreement with Seikagaku Corporation (Japan) on exclusive
distribution
right of ARTZ in the ROC.
Signed
an agreement with Switzerland-based Vifor International
on exclusive
distribution
right of iron therapies in the ROC.
December
2000
Signed
an agreement with IVAX ASIA LTD on exclusive distribution
right of
Elmiron
in the ROC.
Signed
an agreement with JANSSEN CILAG Taiwan on exclusive distribution
right
of Regranex in the ROC.
May
2002
Signed
an OTC sponsorship agreement with Masterlink Securities
Corporation.
June
2002
Changed
company name into Ocean Bright Biotech Co., Ltd.
August
2002
Converted
NT$25 million of earnings into capital and had a capital
increase
by
NT$ 70 million of cash; the total registered capital was
increased to
NT$100
million. |
 |
October
2002
Signed
an agreement with Genovate Biotechnology on
exclusive
distribution right of Paclitaxel.
April 2003
Obtained
approval from the Securities and Futures
Commission
of the Ministry of Finance to go public.
June 2003
Converted
NT$40.93 million of employee bonuses and
earnings
into additional working capital, making a total
registered
capital of NT$140.93 million.
September 2003
Signed
an agreement with YaGe (transliteration)
Biotechnology
on exclusive distribution right of
in
the ROC.
October 2003
Received
an approval from the Gretai Securities Market to
be
listed as an OTC stock.
October 2003
Signed
an agreement with Taiwan Branch of Servier
International(Singapore)
on distribution right of Dimicron MR.
November 2003
Signed
an agreement with Genovate Biotechnology to
co-develop
LNC products.
Signed
an agreement with Seikagaku Corporation (Japan)
on
chief distribution right of Artz in China. |
|
|
|
|
|
